Antiplatelet therapy in neuroendovascular therapeutics

被引:39
作者
Fiorella, D
Thiabolt, L
Albuquerque, FC
Deshmukh, VR
McDougall, CG
Rasmussen, PA
机构
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[2] Boston Sci Neurovasc, Fremont, CA 94538 USA
[3] Barrow Neurol Inst, Phoenix, AZ 85013 USA
关键词
D O I
10.1016/j.nec.2005.03.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Our understanding of the pharmacology of antiplatelet therapy continues to evolve rapidly. Although the existing data are primarily generated in the setting of interventional and preventative cardiology studies, these data may be extrapolated to guide the rational application of these agents in neuroendovascular procedures. Platelet function testing represents an increasingly available and practical method by which to verify the adequacy of therapy and guide clinical decision making. The optimal application of these agents will undoubtedly improve the risk profile of neuroendovascular procedures, increase the success rate of acute stroke intervention, and facilitate more effective secondary stroke prevention.
引用
收藏
页码:517 / +
页数:25
相关论文
共 102 条
[91]   Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study) [J].
Tcheng, JE ;
Talley, JD ;
O'Shea, JC ;
Gilchrist, IC ;
Kleiman, NS ;
Grines, CL ;
Davidson, CJ ;
Lincoff, AM ;
Califf, RM ;
Jennings, LK ;
Kitt, MM ;
Lorenz, TJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (10) :1097-1102
[92]  
Tcheng JE, 2000, LANCET, V356, P2037
[93]  
Tong FC, 2000, AM J NEURORADIOL, V21, P1750
[94]   Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade [J].
Topol, EJ ;
Lincoff, AM ;
Califf, RM ;
Tcheng, JE ;
Kleiman, NS ;
Adelman, AG ;
Burton, JR ;
Talley, JD ;
Ivanhoe, RJ ;
Ducas, C ;
Cheung, PK ;
Schick, U ;
Badard, D ;
Kramer, J ;
Leary, J ;
Snyder, H ;
Wilson, R ;
Dearen, M ;
Caramori, P ;
Webber, S ;
Taylor, J ;
Ferrando, T ;
Cohen, E ;
Balleza, L ;
Rouse, C ;
Hogg, N ;
Kelly, T ;
Alston, S ;
Webb, J ;
Buller, E ;
Ricci, DR ;
Mockman, S ;
Tanguay, JF ;
Poitras, AM ;
Timis, G ;
Davey, D ;
Coleman, P ;
Herrold-Runge, P ;
O'Neill, BJ ;
Foshey, K ;
Fitzgerald, N ;
Almond, D ;
Kostuk, W ;
White, J ;
Oskalns, R ;
Gottlieb, R ;
Koren, P ;
Palazzo, D ;
Azrin, M ;
Barry, MB .
LANCET, 1998, 352 (9122) :87-92
[95]   Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial [J].
Topol, EJ ;
Mark, DB ;
Lincoff, AM ;
Cohen, E ;
Burton, J ;
Kleiman, N ;
Talley, D ;
Sapp, S ;
Booth, J ;
Cabot, CF ;
Anderson, KM ;
Califf, RM .
LANCET, 1999, 354 (9195) :2019-2024
[96]  
Topol EJ, 1997, NEW ENGL J MED, V336, P1689
[97]   Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. [J].
Topol, EJ ;
Moliterno, DJ ;
Herrmann, HC ;
Powers, ER ;
Grines, CL ;
Cohen, DJ ;
Cohen, EA ;
Bertrand, M ;
Neumann, FJ ;
Stone, GW ;
DiBattiste, PM ;
Demopoulos, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1888-1894
[98]   Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease [J].
Tran, H ;
Anand, SS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (15) :1867-1874
[99]   Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries [J].
Ueda, T ;
Sakaki, S ;
Nochide, I ;
Kumon, Y ;
Kohno, K ;
Ohta, S .
STROKE, 1998, 29 (12) :2568-2574
[100]  
Wallace RC, 1997, AM J NEURORADIOL, V18, P1257